Structure-activity relationships of a series of novel topical corticosteroids

Popper, T. L.; Gentles, Margaret Jevnik; Kung, Ted T.; Berkenkopf, Joseph W.; Lutsky, Barry N.; Watnick, Arthur S.; Shapiro, Elliot L.

doi:10.1016/0022-4731(87)90157-9

Cited by 23 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mometasone furoate 0.1 % cream is a new corticosteroid for topical use [1,2]. The com pound is nonfluorinated and when dispensed in a fatty cream vehicle it is normally rated into the EEC group III of topical corticoste roids.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Bioactivity of Mometasone Furoate 0.1% Fatty Cream, Betamethasone Dipropionate 0.05% Cream and Betamethasone Valerate 0.1% Cream in Humans

Bjerring¹

1993

Skin Pharmacol Physiol

View full text Add to dashboard Cite

The bioactivity of a novel topical glucocorticosteroid, mometasone furoate 0.1 % fatty cream was compared with betamethasone dipropionate 0.05% cream and betametasone valerate 0.1% cream. An ultraviolet light (UV-B)-induced inflammation assay in humans was used, and the combined effect of a single, open application of the corticosteroids was evaluated. Reduction of UV-B induced inflammation was monitored by laser Doppler blood flowmetry, clinical skin scoring and skin reflectance spectrophotometry. Skin scoring and reflectance spectrophotometry were found unsuitable because one of the cream vehicles contained titanium dioxide which shielded skin erythema. Laser Doppler blood flowmetry showed that mometasone furoate 0.1 % fatty cream was more than twofold better in reducing UV-B-induced inflammation than betamethasone dipropionate 0.05% cream and betametasone valerate 0.1 % cream, and that the effect was sustained for at least 24 h after a single application.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of the Bioactivity of Mometasone Furoate 0.1% Fatty Cream, Betamethasone Dipropionate 0.05% Cream and Betamethasone Valerate 0.1% Cream in Humans

Bjerring¹

1993

Skin Pharmacol Physiol

View full text Add to dashboard Cite

show abstract

“…In the past, clinical trials have shown that the antiinflammatory potential of MF is similar to triamcinolone [13,14] and stronger than the efficacy of betamethasone [9,10]. Therefore, MF was introduced as a member of the subgroup of glucocorticosteroids with high clinical efficacy.…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, a number of new corticosteroids have been developed. Mometasone furoate (MF) has been introduced as a very potent corticosteroid associated with a low risk of systemic and topical side effects [9,10]. In the past, many clinical studies confirmed the efficacy in inflammatory skin diseases accompanied by low and rare adverse effects [11][12][13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Effects of Mometasone Furoate on Human Keratinocytes and Fibroblasts in vitro

Wach

Bosserhoff

Kurzidym

et al. 1998

Skin Pharmacol Physiol

View full text Add to dashboard Cite

The long-term treatment of inflammatory skin diseases with topical glucocorticoids is limited by their side effects such as skin atrophy, delayed wound healing and striae distensae. Mometasone furoate (MF) is a newly synthesized glucocorticoid with the advantage of increasing efficacy and reducing the number of adverse effects. The aim of our study was to compare the effects of MF and conventional fluorinated corticosteroids on a human keratinocyte cell line (HaCat) and human skin fibroblasts in vitro. Monolayer cultures of these cell lines were exposed to different concentrations of the active compounds for 5 days to analyze the influence on morphology and proliferation. Chemotaxis of HaCat cells and fibroblasts was studied in blind-well Boyden chambers using collagen type I and fibroblast-conditioned medium as a chemoattractant. Additionally, fibroblasts were used to investigate the contraction of collagen gels since lattice contraction appears to model the contraction of skin wounds. All glucocorticoids tested influenced fibroblast and keratinocyte proliferation in a dose-dependent manner, yet the effect was clearly more marked with fluorinated corticosteroids than with MF. Similar effects were obtained using the chemotaxis assay. At low concentrations (10^–9 M) MF exerted almost no influence, while the conventional fluorinated substances inhibited direct migration significantly. Contraction of collagen gels was inhibited completely by betamethasone valerate at high concentrations (10^–5– 10^–3 M), but only partially inhibited by MF at its highest concentration (10^–3 M). Although MF reveals high anti-inflammatory activity similar to that known for conventional fluorinated derivatives of corticosteroids, the study shows that MF has less effect in the tested in vitro systems. Therefore, it remains to be seen whether these data might indicate the possibility of a dissociation between the inflammatory activity and the inhibition of the biosynthetic capacities of fibroblasts and keratinocytes by modification of the steroidal structure of corticosteroids.

show abstract

“…34 FP is halogenated at both the 6α and the 9α position. 35 Adding a methyl group to the 16-carbon position abolished mineralocorticoid activity. Topical potency was increased by adding an esterified lipophilic group to the 5-carbon ring (17α) position.…”

Section: Structure-activity Relationshipmentioning

confidence: 99%

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated

Scadding¹

2010

JAA

View full text Add to dashboard Cite

Seasonal allergic rhinitis (SAR) is increasing in prevalence such that 1 in 4 persons is affected in the UK. It represents a considerable burden of disease since in a significant proportion of individuals the severity of nasal-ocular symptoms has an important effect on daily activity, performance and quality of life. Intranasal steroids (INS) form the mainstay of treatment, having been shown in meta-analyses to be superior to oral antihistamines, intranasal antihistamines and anti-leukotrienes. Fluticasone propionate is an established INS for the treatment of rhinitis, including SAR. Its favorable pharmacological profile combining high local efficacy with low systemic bioavailability has established fluticasone propionate as an effective intervention. The more recent introduction of structurally related fluticasone furoate with similar but enhanced pharmacological characteristics with a novel delivery device may confer further therapeutic advantages.

show abstract

Structure-activity relationships of a series of novel topical corticosteroids

Cited by 23 publications

References 10 publications

Comparison of the Bioactivity of Mometasone Furoate 0.1% Fatty Cream, Betamethasone Dipropionate 0.05% Cream and Betamethasone Valerate 0.1% Cream in Humans

Comparison of the Bioactivity of Mometasone Furoate 0.1% Fatty Cream, Betamethasone Dipropionate 0.05% Cream and Betamethasone Valerate 0.1% Cream in Humans

Effects of Mometasone Furoate on Human Keratinocytes and Fibroblasts in vitro

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated

Contact Info

Product

Resources

About